BioMarin

YTD

ALL

Trade BioMarin 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About BMRN

BioMarin Pharmaceutical, Inc. engages in the development and commercialization of therapies for people with serious and life-threatening rare diseases and medical conditions. Its pipeline products include Valoctocogene roxaparvovec, Vosoritide, and BMN 307.

CEO

Alexander Hardy

CEOAlexander Hardy

Employees

3,221

Employees3,221

Headquarters

San Rafael, California

HeadquartersSan Rafael, California

Founded

1997

Founded1997

Employees

3,221

Employees3,221

BMRN Key Statistics

Market cap

10.29B

Market cap10.29B

Price-Earnings ratio

39.07

Price-Earnings ratio39.07

Dividend yield

—

Dividend yield—

Average volume

2.17M

Average volume2.17M

High today

$54.09

High today$54.09

Low today

$52.64

Low today$52.64

Open price

$53.78

Open price$53.78

Volume

1.13M

Volume1.13M

52 Week high

$66.28

52 Week high$66.28

52 Week low

$50.76

52 Week low$50.76

Stock Snapshot

With a market cap of 10.29B, BioMarin(BMRN) trades at $53.24. The stock has a price-to-earnings ratio of 39.07.

During the trading session on 2026-05-14, BioMarin(BMRN) shares reached a daily high of $54.09 and a low of $52.64. At a current price of $53.24, the stock is +1.1% higher than the low and still -1.6% under the high.

Trading activity shows a volume of 1.13M, compared to an average daily volume of 2.17M.

The stock's 52-week range extends from a low of $50.76 to a high of $66.28.

BMRN News

TipRanks 7h

BioMarin Extends BMN 351 Duchenne Study, Keeping Long-Term Data in Focus for Investors

Biomarin Pharmaceutical Inc. (BMRN) announced an update on their ongoing clinical study. Unlock hedge fund-level data and powerful investing tools for smarter,...

TipRanks 3d

Top BioMarin Executive Makes Notable Move With Latest Stock Sale

New insider activity at BioMarin Pharmaceutical ( (BMRN) ) has taken place on May 11, 2026. Unlock hedge fund-level data and powerful investing tools for smart...

Simply Wall St 3d

BioMarin Pharmaceutical Valuation Check As 2026 Guidance Rises And VOXZOGO Data Strengthens

BioMarin Pharmaceutical (BMRN) is back in focus after raising its full year 2026 revenue outlook to US$3.83b to US$3.93b and releasing fresh VOXZOGO clinical da...

Analyst ratings

78%

of 27 ratings

Buy

77.8%

Hold

22.2%

Sell

More BMRN News

TipRanks 4d

BioMarin reinstated with a Neutral at Goldman Sachs

Goldman Sachs reinstated coverage of BioMarin (BMRN) with a Neutral rating and $69 price target following the completion of the Amicus acquisition. While the sh...

Simply Wall St 5d

Is It Time To Reassess BioMarin Pharmaceutical After Its Multi‑Year Share Price Slide

If you are wondering whether BioMarin Pharmaceutical's current share price reflects its true value, a useful starting point is understanding how the market has...

People also own

Based on the portfolios of people who own BMRN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.